AI Drug Discovery Leaders Gain a Competitive Edge with Telesis Bio’s Gibson SOLA® Platform, Generating Development Candidates Faster

SAN DIEGO–(BUSINESS WIRE)–Telesis Bio today announced recent commercial licensing agreements with several AI-native drug discovery companies.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks